IL113720A0 - Diagnostics and treatments for cancers expressing tyrosine phosphorylated CRKL protein - Google Patents

Diagnostics and treatments for cancers expressing tyrosine phosphorylated CRKL protein

Info

Publication number
IL113720A0
IL113720A0 IL11372095A IL11372095A IL113720A0 IL 113720 A0 IL113720 A0 IL 113720A0 IL 11372095 A IL11372095 A IL 11372095A IL 11372095 A IL11372095 A IL 11372095A IL 113720 A0 IL113720 A0 IL 113720A0
Authority
IL
Israel
Prior art keywords
diagnostics
treatments
tyrosine phosphorylated
phosphorylated crkl
crkl protein
Prior art date
Application number
IL11372095A
Other languages
English (en)
Original Assignee
Los Angeles Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Los Angeles Childrens Hospital filed Critical Los Angeles Childrens Hospital
Publication of IL113720A0 publication Critical patent/IL113720A0/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL11372095A 1994-05-13 1995-05-14 Diagnostics and treatments for cancers expressing tyrosine phosphorylated CRKL protein IL113720A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/242,513 US5667981A (en) 1994-05-13 1994-05-13 Diagnostics and treatments for cancers expressing tyrosine phosphorylated CRKL protein
PCT/US1995/005957 WO1995031545A2 (en) 1994-05-13 1995-05-12 Diagnostics and treatments for cancers expressing tyrosine phosphorylated crkl protein

Publications (1)

Publication Number Publication Date
IL113720A0 true IL113720A0 (en) 1995-10-31

Family

ID=22915067

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11372095A IL113720A0 (en) 1994-05-13 1995-05-14 Diagnostics and treatments for cancers expressing tyrosine phosphorylated CRKL protein

Country Status (10)

Country Link
US (1) US5667981A (ja)
EP (1) EP0759986B1 (ja)
JP (1) JPH10503365A (ja)
AT (1) ATE175996T1 (ja)
AU (1) AU691927B2 (ja)
CA (1) CA2190161A1 (ja)
DE (1) DE69507470D1 (ja)
IL (1) IL113720A0 (ja)
WO (1) WO1995031545A2 (ja)
ZA (1) ZA953912B (ja)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7309692B1 (en) * 1996-07-08 2007-12-18 Board Of Regents, The University Of Texas System Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1
PT983510E (pt) 1997-05-20 2004-06-30 Univ Erasmus Reconhecimento de produtos geneticos especificos de tumor em cancro
US6686165B2 (en) 1997-05-20 2004-02-03 Erasmus Universiteit Rotterdam Recognition of tumor-specific gene products in cancer
AU4567299A (en) * 1998-06-22 2000-01-10 Feshchenko, Elena A. C-cbl suppression of neoplastic transformation
US20080280771A1 (en) * 2000-02-08 2008-11-13 Regents Of The University Of Michigan Protein MicroarraySystem
US20050230315A1 (en) * 2003-01-13 2005-10-20 Regents Of The University Of Michigan Protein microarray system
EP1267305B1 (en) * 2000-03-23 2006-03-15 Japan Science and Technology Agency Cell lineage extracting method
US6919173B2 (en) 2001-09-10 2005-07-19 Meso Scale Technologies, Llc. Assay buffer, compositions containing the same, and methods of using the same
US7718387B2 (en) 2001-09-20 2010-05-18 Board Of Regents, The University Of Texas System Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays
WO2003087760A2 (en) * 2002-04-05 2003-10-23 Cell Signaling Technology, Inc. Methods for detecting bcr-abl signaling activity in tissues using phospho- specific antibodies
US20060063156A1 (en) * 2002-12-06 2006-03-23 Willman Cheryl L Outcome prediction and risk classification in childhood leukemia
WO2004060055A1 (ja) * 2002-12-27 2004-07-22 Chugai Seiyaku Kabushiki Kaisha Wt1遺伝子トランスジェニック動物
EP1682571A4 (en) * 2003-10-27 2006-12-06 Medvet Science Pty Ltd BICOORDIN PATTERN AND METHODS OF USE
WO2006086111A2 (en) * 2005-02-10 2006-08-17 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
EP2303913A4 (en) * 2008-06-20 2013-07-24 Univ Texas TARGETING PEPTIDES OF CRKL
WO2012030738A2 (en) * 2010-08-30 2012-03-08 Beckman Coulter, Inc. Complex phosphoprotein activation profiles
EP2890706A1 (en) 2012-08-31 2015-07-08 Westfälische Wilhelms-Universität Münster Methods and peptides for preventing and treating a bcr-abl and a c-abl associated disease
JP7300642B2 (ja) * 2019-06-14 2023-06-30 国立大学法人浜松医科大学 特発性肺線維症の予後予測方法
CN115991789B (zh) * 2022-07-14 2024-06-04 华中科技大学 一种基于sh2超亲体的融合蛋白及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH082799B2 (ja) * 1987-03-06 1996-01-17 秀雄 麦島 骨髄線維症治療剤
WO1993003377A1 (en) * 1991-07-31 1993-02-18 Ziltener Hermann J Method for the detection of phosphotyrosine residues
CA2054602C (en) * 1991-10-31 2003-04-22 Anthony Pawson Method for assaying for a substance that affects an sh2-phosphorylated ligand regulatory system

Also Published As

Publication number Publication date
ATE175996T1 (de) 1999-02-15
AU2689095A (en) 1995-12-05
ZA953912B (en) 1996-01-16
WO1995031545A2 (en) 1995-11-23
EP0759986A1 (en) 1997-03-05
CA2190161A1 (en) 1995-11-23
US5667981A (en) 1997-09-16
DE69507470D1 (de) 1999-03-04
EP0759986B1 (en) 1999-01-20
WO1995031545A3 (en) 1996-08-01
JPH10503365A (ja) 1998-03-31
AU691927B2 (en) 1998-05-28

Similar Documents

Publication Publication Date Title
IL113720A0 (en) Diagnostics and treatments for cancers expressing tyrosine phosphorylated CRKL protein
ES2159318T3 (es) Inhibidores de la proteina quinasa c.
NO970039D0 (no) Fremgangsmåte for inhibering av cancer matastaser ved oral administrering av opplöselig modifisert sitruspektin
ATE408422T1 (de) Methode zur hemmung immunstimulatorischer mit dna assoziierter antworten
WO1998035693A3 (en) Detection and modulation of the iaps and naip for the diagnosis and treatment of proliferative disease
GB9411671D0 (en) Tumor diagnosis and prognosis
TR200000662T2 (tr) Doğal-olmayan seçici agonistler kullanılarak kemik hacminin arttırılması yöntemi.
WO1999058692A3 (en) Human apoptosis associated proteins
AU2385095A (en) Tumor suppressor gene and methods for detection of cancer, monitoring of tumor progression and cancer treatment
EP1163515A4 (en) THERAPEUTIC AND DIAGNOSTIC AGENTS FOR DISEASES WITH DISTURBED GLUCOSE TOLERENCE
AU3392901A (en) Proteins
WO1999028461A3 (en) Methods and means for inducing apoptosis by interfering with bip-like proteins
HK1011560A1 (en) Method of diagnosing and treating epithelioma
DE69229394D1 (de) Zusammensetzungen und methoden zur behandlung von kleinzell und nicht-kleinzell lungenkrebsen
AU2932100A (en) Neurodegenerative disorder related gene
EP1019092A4 (en) THERAPEUTIC AND DIAGNOSTIC TOOLS FOR POOR CARBOHYDRATE TOLERANCE
IL189502A0 (en) Methods and compositions for inhibiting neoplastic cell growth
DE69534753D1 (de) Nierenpolycystose-gen
DE69637123D1 (de) Die expression von cyclin g1 in tumoren
GB9800378D0 (en) Proteome analysis
EP0846263A4 (en) METHOD AND KIT FOR EVALUATING THE METASTATIC TREND OF TUMORS
AU4654097A (en) Rdgb-proteins
WO2003029482A3 (en) Diagnosing, treating, and preventing cancer using cables
WO2001034792A3 (en) Compositions and methods for the diminution or elimination of various cancers
WO1999064596A3 (en) Proteins regulating gene expression